Market analysis of diabetes drug

Feb 17
07:33

2012

David Yvon

David Yvon

  • Share this article on Facebook
  • Share this article on Twitter
  • Share this article on Linkedin

With the rapid and sustainable development of the Chinese economy, Chinese residents’ dietary and nutritional statuses have been dramatically improved.

mediaimage

But there is a problem of the evolution of trophic structure imbalances and nutritional deficiencies which may lead to the occurrence of non-communicable,Market analysis of diabetes drug Articles chronic metabolic syndrome and other diseases. Diabetes is a group of diseases with greater harm. It has seriously affected the physical and mental health of people.

Diabetes has become the world's fifth largest cause of death is considered to be second only to cardiovascular diseases and malignant tumors resveratrol of non-communicable diseases. The global diabetic population in 2005 has expanded to 220 million people, many people there is the risk of impaired glucose tolerance disorders. In developing countries, adult prevalence of high and middle-aged man has become at high risk of this disease.

Diabetes is a human nutritional and metabolic disorders caused by endocrine disease, with sustained high blood sugar as its basic biochemical characteristics, due to insulin in target cells can not play a normal physiological role, as well as the inadequate supply of insulin, protein, fat and simple sugars into disorder, resulting in patients water and electrolyte metabolism disorders and systemic diseases. Disease according to the pathological features into two categories: insulin-dependent diabetes and non-insulin-dependent diabetes.

Hyperglycemia in patients belonging to more than 90% of type II diabetes, type II diabetes is a heterogeneous disease caused by genetic factors, environmental factors, resulting in blood sugar in insulin secretion, insulin resistance and the dynamic role in cell constant scalar imbalance. The ferocious of these diseases on human health caused great harm. It has been attached great importance by the World Health Organization.

China in the development process to the well-off society, fat and carbohydrate intake has not been reasonable control, aging and multi-directional stress factors, and the incidence of diabetes rates have increased year by yea. In the 1990s the medium-term compared to many parts of the average annual increase speed of a thousandth of the Beijing area of diabetes has raised from 4.6% to 6.4%, Chinese patients with diabetes has more than 4000 people. Low glucose tolerance docetaxel, impaired glucose regulation function similar to the number of diabetic patients, thus becoming all the way up the power to promote the diabetes drug market.

In the past 40 years, the world has developed over one hundred kinds of antihyperglycemic drugs, of which 30% of the species is currently active in the Chinese market, these species are composed mainly by oral hypoglycemic agents and insulin two categories. The treatment of diabetes is common and personalized features, therefore, the clinical use of unilateral, compound, and joint administration of the program.

Classified by the mechanism, the main commonly used anti-diabetic chemicals are insulin, insulin analogues, sulfonylurea, biguanides, alpha-glucosidase inhibitor, thiazolyl oxazolidine dione derivatives and amino acid derivatives categories varieties. In 2004, among the 200 kinds of medicines selling in Chinese wholesale markets, anti-diabetic prescription drugs has reached more than 2 billion RMB. The annual growth rate is nearly 40 percent, accounting for 61% of the endocrine and metabolic regulation drugs share. The growth rate is 36.36% comparing to the situation in 2003. The overall size of the prescription drug market has reached more than 10 billion RMB. More dose using in clinical trials are about acarbose, metformin, gliclazide, glibenclamide methaqualone, glipizide, glibenclamide, georgia glimepiride and single-component insulin. There are more than 20 varieties.Source:http://www.cospcn.com